[Sign in] [Register]   

EIAab logo

EIAab news detail, please contact if you have any questions about online orders and payment.
Towards a TDP-43-Based Biomarker for ALS and FTLD
Update time:2018-05-25 14:23:00   【 Font: Large  Medium Small


TDP-43 accumulates in nerve cells of nearly all cases of amyotrophic lateral sclerosis (ALS; the commonest form of motor neuron disease) and in the majority of Tau-negative frontotemporal lobar degeneration (FTLD). There is currently no biochemical test or marker of disease activity for ALS or FTLD, and the clinical diagnosis depends on the opinion of an experienced neurologist. TDP-43 has a key role in the pathogenesis of ALS/FTLD. Measuring TDP-43 in easily accessible biofluids, such as blood or cerebrospinal fluid, might reduce diagnostic delay and offer a readout for use in future drug trials. However, attempts at measuring disease-specific forms of TDP-43 in peripheral biofluids of ALS and FTLD patients have not yielded consistent results, and only some of the pathological biochemical features of TDP-43 found in human brain tissue have been detected in clinical biofluids to date. Reflecting on the molecular pathology of TDP-43, this review provides a critical overview on biofluid studies and future directions to develop a TDP-43-based clinical biomarker for ALS and FTLD.



TDP-43 Biomarker Cerebrospinal fluid Amyotrophic lateral sclerosis Frontotemporal dementia TARDBP 

Cited products
Source:Molecular Neurobiology      by E Feneberg, E Gray, K Talbot, et al.
Hot Genes
Top Searches
Why choose EIAAB
Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
Further Information
About us Protein center Bank account Distributors Terms & Conditions Career

Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab


鄂公网安备 42018502005535号